Marcadia Biotech

Next-generation incretin peptide therapeutics for type 2 diabetes

Marcadia was a spinout from The University of Indiana that focused on novel diabetes therapeutics. The company's programs were based on novel insights into the incretin pathways (GLP-1, GIP, glucagon) from the lab of Richard DiMarchi, and the company formed multiple partnerships with Merck and Eli Lilly for these assets. Marcadia was acquired in 2010 by Roche.

Status

Acquired by Roche in 2010

Year of Investment

2007

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Carmel, Indiana